United Therapeutics (STU:UTH) Accounts Payable & Accrued Expense : €339 Mil (As of Mar. 2025)

View and export this data going back to . Start your Free Trial

What is United Therapeutics Accounts Payable & Accrued Expense?

United Therapeutics's quarterly accounts payable & accrued expense increased from Sep. 2024 (€328 Mil) to Dec. 2024 (€329 Mil) and increased from Dec. 2024 (€329 Mil) to Mar. 2025 (€339 Mil).

United Therapeutics's annual accounts payable & accrued expense increased from Dec. 2022 (€217 Mil) to Dec. 2023 (€273 Mil) and increased from Dec. 2023 (€273 Mil) to Dec. 2024 (€329 Mil).

United Therapeutics Accounts Payable & Accrued Expense Historical Data

The historical data trend for United Therapeutics's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

United Therapeutics Accounts Payable & Accrued Expense Chart

United Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

153.71

154.52

217.03

273.27

329.00

United Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															280.69	302.20	327.87	329.00	339.48

United Therapeutics Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

United Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » United Therapeutics Corp (STU:UTH) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

UTHR:USA UTH:Germany

Address

1000 Spring Street, Silver Spring, MD, USA, 20910

Website

https://www.unither.com

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

United Therapeutics Headlines

No Headlines